Spyre Therapeutics, Inc. (SYRE) stock
Close on Nov 17, 2026Market cap $8.27BP/E –Yield –
Spyre Therapeutics, Inc. reported revenue of $0 for fiscal 2025. At the latest close the market valued the company at $8.27B.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $8.27B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 7.51
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$178.92M
Trading
- Next earnings
- Feb 18, 2027 (estimated, after the close)
- Previous close
- $99.37
- Open
- $98.70
- Day's range
- $92.92 – $100.03
- Volume
- 1,109,263
- Average volume (20 days)
- 945,067
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- 52-week range
- $22.13 – $110.64
- RSI (14 days)
- 52.8
- Volatility (1 year)
- 66.7%
- Relative volume
- 0.70×
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | SYRE | S&P 500 | Difference | SYRE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +17.4% | -4.0% | +21.4 pts | ||
| 3 months | -10.3% | -5.0% | −5.3 pts | ||
| Year to date | +186.4% | +8.2% | +178.1 pts | ||
| 1 year | +285.1% | +11.2% | +273.9 pts | ||
| 3 years | +815.2% | +68.5% | +746.7 pts | +109.2% | +19.0% |
| 5 years | -44.7% | +67.3% | −111.9 pts | -11.2% | +10.8% |
| 10 years | -39.5% | +291.6% | −331.1 pts | -4.9% | +14.6% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Spyre Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Results
About Spyre Therapeutics
Pharmaceutical Preparations
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company that creates long-acting monoclonal antibodies and combination therapies to treat inflammatory bowel disease and rheumatic conditions. Its drug development pipeline targets biological pathways including α4β7, TL1A, and IL-23, which are being advanced as individual therapies as well as fixed-dose pairwise combinations. The company focuses on conditions such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Because its product candidates remain in clinical evaluation, Spyre does not currently sell commercial products, though its prospective end-users are individuals suffering from these chronic immune-mediated disorders.
Company profile, executives and historySpyre Therapeutics stock: common questions
What is Spyre Therapeutics's stock price?
SYRE closed at $93.81 on Nov 17, 2026, down 5.60% on the day. Over the past 52 weeks it traded between $22.13 and $110.64.
What is Spyre Therapeutics's market cap?
Spyre Therapeutics was worth $8.27B at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
How much revenue does Spyre Therapeutics make?
Spyre Therapeutics reported revenue of $0 for fiscal 2025.
Does Spyre Therapeutics pay a dividend?
No. Spyre Therapeutics has not paid a cash dividend over the last twelve months.
When does Spyre Therapeutics report earnings next?
Spyre Therapeutics is expected to report Q4 FY2026 results on Feb 18, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has SYRE stock performed over the past year?
Including dividends, SYRE returned +285.1% over the past year, against +11.2% for the S&P 500.
How many SYRE shares are sold short?
12M shares were sold short at the latest FINRA report, 16.54% of the float, or 12.7 days of average trading volume.
Who are Spyre Therapeutics's competitors?
Companies most similar to Spyre Therapeutics by business, industry and size include STTK, ACRS, DNTH, CRVS, MLTX.
See a number that looks wrong?